Zymeworks and Roche agreed on an exclusive worldwide license for ZW209, a DLL3×CD3×CD28 trispecific T cell engager. The verified economics are $55 million upfront after antitrust clearance, $40 million on Phase 1b initiation, up…
Hansoh Pharma and Roche entered a second antibody drug conjugate collaboration covering two undisclosed Hansoh preclinical programs and multiple Roche-proposed targets using Hansoh’s proprietary ADC platform. Hansoh will receive $400 million upfront and $110…
Roche obtained an exclusive worldwide license to Rona Therapeutics’ investigational ALK7-targeting RNA interference program for obesity and metabolic disease. Rona is eligible for up to $100 million in combined upfront and near-term milestone payments,…
Nurix Therapeutics discontinued further clinical development of NX-2127, or zelebrudomide, a dual BTK and IKZF1/3 degrader for B-cell malignancies. Patients already receiving the drug may continue while clinically appropriate, with essential safety monitoring and…
Genentech licensed worldwide rights to Alector’s preclinical AL050 program for $100 million upfront, as much as $1.17 billion in conditional milestones and tiered royalties. AL050 couples engineered GCase to a blood-brain-barrier carrier. The agreement…
Roche agreed to pay Atavistik Bio $70 million upfront for a multi-target research collaboration using Atavistik’s AMPS platform to discover allosteric small molecules in cardiovascular, renal and metabolic disease. Atavistik may receive up to…
Roche and Ionis reported that the 459-patient randomized IMAgINATION Phase 3 trial met its prespecified 37-week proteinuria endpoint in primary IgA nephropathy. Monthly subcutaneous sefaxersen significantly reduced 24-hour urine protein-to-creatinine ratio versus placebo. The…
Roche reported that once weekly enicepatide met both primary endpoints in the randomized Phase 2 CT 388 104 study. At 24 mg, mean HbA1c fell 2.65 percentage points and body weight fell 15.5 percent…
The Phase III CELESTIMO study met its primary progression-free-survival endpoint at an interim analysis, with mosunetuzumab plus lenalidomide producing a statistically significant and company-described clinically meaningful reduction in progression or death versus rituximab plus…
Roche agreed to pay Dualitas Therapeutics $36.5 million upfront for a research collaboration using Dualitas’ DualScreen platform to functionally test more than 300,000 bispecific combinations in immunology and inflammation. Research, development, and commercial milestones…
